Table 1.
Pivotal phase III ICPI studies in OG cancers.
| Trial name | N | ICPI | Combination/comparator arm | Clinical Trials.gov identifier |
|---|---|---|---|---|
| First-line gastric and OGJ | ||||
| CHECKMATE 649 | 1266 | Nivolumab | Capecitabine/5FU/oxaliplatin | NCT02872116 |
| KEYNOTE 062 | 750 | Pembrolizumab | Cisplatin/5FU | NCT02494583 |
| First-line maintenance gastric and OGJ | ||||
| PLATFORM | 770 | Durvalumab | BSC/capecitabine/olaparib | NCT02678182 |
| JAVELIN gastric 100 | 666 | Avelumab | First-line chemotherapy | NCT02625610 |
| Second-line gastric and OGJ | ||||
| KEYNOTE 061 | 720 | Pembrolizumab | Paclitaxel | NCT02370498 |
| KEYNOTE 063 (Asia only) | 360 | Pembrolizumab | Paclitaxel | NCT03019588 |
| Third-line gastric and OGJ | ||||
| JAVELIN gastric 300 | 330 | Avelumab | Irinotecan/paclitaxel/BSC | NCT0262562324 |
| Advanced oesophageal cancer ⩾ two lines | ||||
| CHECKMATE 473 | 390 | Nivolumab | Docetaxel/paclitaxel | NCT02569242 |
| KEYNOTE 181 | 720 | Pembrolizumab | Docetaxel/paclitaxel/irinotecan | NCT02564263 |
5FU, 5-fluoruracil; BSC, best supportive care; ICPI, immune checkpoint inhibitor; N, estimated recruitment; OG, oesophagogastric; OGJ, oesophagogastric junction.